Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: More distant metastases and shorter overall survival after treatment

Head and Neck

Volumn 33, Issue 6, 2011, Pages 780-785

  Lv, Xing ^a   Xiang, Yan Qun ^a   Cao, Su Mei ^a   Qian, Chao Nan ^a   Li, Ning Wei ^a   Guo, Ling ^a   Mai, Hai Qiang ^a   Chen, Qiu Yan ^a   Huang, Pei Yu ^a   Luo, Donghua ^a   Cao, Ka Jia ^a   Hong, Ming Huang ^a   Guo, Xiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

nasopharyngeal carcinoma; prognosis; serum VEGF

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SEX DIFFERENCE;

ADULT; AGED; CARCINOMA; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955884042     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21541     Document Type: Review

References (31)

1. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312. (Pubitemid 20066717)
2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N,. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309. (Pubitemid 20066716)
3. Wakisaka N, Wen QH, Yoshizaki T, et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope 1999; 109: 810-814. (Pubitemid 29227932)
4. Guang-Wu H, Sunagawa M, Jie-En L, et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension nasopharyngeal carcinoma. Laryngoscope 2000; 110: 2066-2069.
5. Qian CN, Zhang CQ, Guo X, et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 2000; 88: 255-261. (Pubitemid 30051806)
6. Li YH, Shao JY, Li S, Zou BY, Huang HQ, Guan ZZ,. Clinical significance of quantitative analysis of serum VEGF, CD44s, and MMP-3 protein in nasopharyngeal carcinoma. [Article in Chinese] Ai Zheng 2004; 23: 1060-1064.
7. Guo X, Cao SM, Hong MH, et al. Clinical value of vascular endothelial growth factor detection in forecasting distant metastasis risk of nasopharyngeal carcinoma. [Article in Chinese] Ai Zheng 2004; 23: 1171-1175.
8. Choi KS, Bae MK, Jeong JW, Moon HE, Kim KW,. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 2003; 36: 120-127.
9. Pan J, Kong L, Lin S, Chen G, Chen Q, Lu JJ,. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. Laryngoscope 2008; 118: 1970-1975.
10. Krishna SM, James S, Balaram P,. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 2006; 115: 85-90. (Pubitemid 41772484)
11. Sui J, Cao XJ, Li XJ,. Correlation between the vascular endothelial growth factor C expression and lymph node metastasis in human nasopharyngeal carcinoma. [Article in Chinese] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008; 43: 524-528.
12. Li YH, Hu CF, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 2008; 6: 1.
13. Zhao GG, Xiang XJ, He YJ,. Expression and clinical significance of vascular endothelial growth factor C and D in nasopharyngeal carcinoma. [Article in Chinese] Ai Zheng 2007; 26: 90-95.
14. He SQ, Zhang WY,. Relationship between the expressions of KaI1, nm23, ETS-1, VEGF and microvascular density and clinical significance in nasopharyngeal carcinoma. [Article in Chinese] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2006; 41: 813-817.
15. Shi XY, Hu GQ, Yuan XL, Li HY, Liu YQ, Ma D,. Relationship between VEGF-C expression and nasopharyngeal carcinoma proliferation and metastasis. [Article in Chinese] Zhonghua Zhong Liu Za Zhi 2006; 28: 364-367.
16. Sha D, He YJ,. Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma. [Article in Chinese] Ai Zheng 2006; 25: 229-234.
17. Werther K, Bülow S, Hesselfeldt P, Jespersen NF, Svendsen MN, Nielsen HJ,. VEGF concentrations in tumour arteries and veins from patients with rectal cancer. APMIS 2002; 110: 646-650. (Pubitemid 35335134)
18. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR,. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-220. (Pubitemid 23084552)
19. Taichman NS, Young S, Cruchley AT, Taylor P, Paleolog E,. Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol 1997; 62: 397-400. (Pubitemid 27431612)
20. Linder C, Linder S, Munck-Wikland E, Auer G, Aspenblad U, Strander H,. Evaluation of tissue and serum VEGF in patients with head and neck carcinoma. Angiogenesis 1998; 2: 365-372. (Pubitemid 128514263)
21. Salven P, Teerenhovi L, Joensuu H,. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 3167-3172. (Pubitemid 27444212)
22. Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002; 8: 3193-3197. (Pubitemid 35155030)
23. Salven P, Ruotsalainen T, Mattson K, Joensuu H,. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998; 79: 144-146. (Pubitemid 28201685)
24. Yu XM, Lo CY, Lam AK, Lang BH, Leung P, Luk JM,. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 2008; 144: 934-940; discussion 940-941.
25. Karayiannakis AJ, Bolanaki H, Syrigos KN, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003; 194: 119-124. (Pubitemid 36428891)
26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. (Pubitemid 46089673)
28. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
29. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
30. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. (Pubitemid 46089672)
31. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)